Article

HER2CLIMB-02: Randomized, double-blind phase 3 trial of tucatinib and trastuzumab emtansine for previously treated HER2-positive metastatic breast cancer

Clinical Advances in Hematology and Oncology
ISSN: 15430790
0Citations
Citations of this article
19Readers
Mendeley users who have this article in their library.

Cite

CITATION STYLE

APA

HER2CLIMB-02: Randomized, double-blind phase 3 trial of tucatinib and trastuzumab emtansine for previously treated HER2-positive metastatic breast cancer. (2024, January 1). Clinical Advances in Hematology and Oncology. Millennium Medical Publishing, Inc.

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free